Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03118986 · ClinicalTrials.gov registry record · Phase 2
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
A Phase 2 study of Oncology and Nausea, sponsored by The Hospital for Sick Children.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 10
- Study locations
NCT03118986 is a Phase 2 study of Oncology and Nausea that is actively recruiting participants, run by The Hospital for Sick Children. The registered enrollment target is 200 participants, below the 519-participant average among 24 other Oncology trials with a reported enrollment target (61% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT03118986, a Phase 2 study of Oncology and Nausea, is actively recruiting participants, sponsored by The Hospital for Sick Children.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 10
- Study locations
Study Summary
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy
Conditions Studied
Interventions
- DRUG Olanzapine
- DRUG Placebo Oral Tablet
Study Locations (10)
California
- University of California - San Francisco
Missouri
- The Children's Mercy Hospital - Kansas City
New York
- Columbia University/Morgan Stanley Children's Hospital - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- Nationwide Children's Hospital - Columbus
South Carolina
- Medical University of South Carolina - Charleston
Manitoba
- Cancer Care Manitoba - Winnipeg
Ontario
- Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03118986
The ClinicalTrials.gov registry entry for NCT03118986 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 519-participant average among 24 other Oncology trials with a reported enrollment target (61% lower). The listed sponsor is The Hospital for Sick Children, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Oncology appearing as the primary indexed condition, and to 2 interventions - of which Olanzapine is the first listed.
NCT03118986 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT03118986 about?
NCT03118986 is a clinical study titled "RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy". Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, expe...
What is the current status of trial NCT03118986?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2017-08-10. Estimated completion is 2026-04.
What conditions does trial NCT03118986 study?
This clinical trial studies the following conditions: Oncology, Nausea, Hematopoietic System--Cancer, Vomiting in Infants and/or Children.
What interventions are being tested in trial NCT03118986?
The interventions under investigation include: Olanzapine (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03118986?
This trial is sponsored by The Hospital for Sick Children, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03118986 being conducted?
This trial has 10 study locations across California, Missouri, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oncology
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
COMPLETED · Phase 2
-
Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients
RECRUITING · Phase 4
-
Clinical Alternatives for Reducing Harm Using E-cigarettes
RECRUITING · NA
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.